Board summary
Key figures
43,800
Registered population
56.0% aged 18–64
25.3%
Aged 65+
ICB 20.0% · England 17.9%
4.2%
Ethnic minority (non-White)
2.9% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
8,194
Hypertension register
+6.04% in 3 yrs · England +5.60%
442
SMI register
67.6% of Ribble Valley's
839
COPD register
Reviews +1.10% in 3 yrs
Forecast to 2030
9,712
Hypertension patients, 2030
+1,518 on today
72.4%
QRISK ≥20% on statins, 2030
+4.80pp over 3 yrs
6.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension target trends lag behind England.
Although 74.9% of hypertension patients meet target (England 70.3%), three-year achievement changed by -1.5% (England +3.6%) and QRISK >=20% lipid therapy is 61.5%.
Estimated unreviewed asthma patients and smoke recording.
Despite 70.6% review coverage across 3,276 asthma patients, a scale estimate leaves 964 unreviewed, while aged 6-19 second-hand smoke recording is 71.5% (England 78.8%).
Breast and cervical screening exceed national rates.
Breast screening coverage aged 53 to 70 is 81.1% (England 69.9%) and cervical screening aged 25-49 is 75.9% (England 66.8%).
Population, age and ethnicity
Older patients form 25.3% of the list, while White residents comprise 95.8%
Across 43,800 registered patients in four practices, 25.3% (11,087) are aged 65+, exceeding Ribble Valley (23.1%), NHS Lancashire and South Cumbria Integrated Care Board (20.0%) and England (17.9%). Ages 18-64 comprise 56.0% (borough 58.7%, ICB 60.4%, England 62.7%), and 0-17 comprise 18.7% (borough 18.2%, ICB 19.6%, England 19.6%). List size is projected to grow 4.2% to 2030 (borough 4.4%, ICB 1.7%, England 2.3%; unverified methodology). Census usual residents in associated areas are 95.8% White (borough 96.2%, ICB 87.8%, England 81.1%), giving a 4.2% ethnic minority share, though resident data differs from registered lists.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Ribble Valley local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Ribble Valley LA) | 1,466 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Ribble Valley LA) | 662 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Ribble Valley LA) | 13.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Zero registered patients live in Core20 areas across the network
The PCN records an average IMD decile of 7.9, above Ribble Valley (7.8), England (5.5) and NHS Lancashire and South Cumbria ICB (5.0). Across registered patients, 0.0% live in Core20 areas, matching Ribble Valley (0.0%) but below England (21.0%) and the ICB (30.6%), with 0 of 29 associated LSOAs in deciles 1 or 2. Area indices may not reflect dispersed rural vulnerability; the PCN manages 442 severe mental illness patients, holding 67.6% of the borough's register.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
442
SMI register
1.01% recorded prevalence
171
Learning disability register
0.39% recorded prevalence
13
Care homes, 499 beds
In the PCN catchment
8.4%
Provide unpaid care
Ribble Valley, Census 2021
The PCN records 442 severe mental illness patients (1.0%, matching England) and 171 learning disability patients (0.4% vs England 0.6%), representing 67.6% and 63.1% of borough registers. Catchment facilities include 13 care homes (499 beds), alongside an estimated PCN ceiling of 3,679 unpaid carers and a borough snapshot of 3 people sleeping rough.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 87.2% (Ribble Valley 84.1%, ICB 79.8%, England 83.4%), but three-year progress (+0.8 pp) trailed England (+4.4 pp). Other published checks include BMI at 87.8% (England 82.1%). Unrecorded elements cannot imply completion.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,194
Hypertension register
+6.04%
Register growth, 3 yrs
Ribble Valley +4.80% · England +5.60%
−0.70pp
BP control, under 80
≤140/90 · +0.02pp aged 80+
+1,518
More patients by 2030
Forecast 9,712 (21.03%)
Hypertension case-finding and control
Hypertension register prevalence is 18.7% (8,194 patients), above England (15.2%) and the ICB (17.2%), and in line with Ribble Valley (18.7%), though crude rates are not age-adjusted. While 89.7% of patients had a recent blood pressure check and current control is strong (74.9% treated to target vs England 70.3%), three-year treatment-to-target progress fell 1.5% (England +3.6%). Similarly, control in under-80s (72.2% vs England 67.8%) fell 1.0% over three years (England +3.2%). With blood pressure control slipping behind England over three years despite higher current achievement, the PCN should prioritise targeted review and titration for uncontrolled patients.
Lipids and statins
Primary prevention lipid treatment covers 61.5% of patients with QRISK ≥ 20%, trailing England (63.6%) and Ribble Valley (62.3%), while statin therapy in diabetes aged 40+ without CVD (71.2%) lags England (73.2%). Fewer at-risk patients receive lipid-lowering therapy than England rates, indicating potential scope for proactive recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 115,827 | £1.50 | £1.64 | £1.86 | £173,740 |
| Cardiovascular (all), 2025 | 147,835 | £3.36 | £3.38 | £3.33 | £496,726 |
In 2026, the PCN prescribed 115,827 lipid-regulating items at £1.50 per item (annual spend £173,740), below England (£1.86), Ribble Valley (£1.69) and the ICB (£1.64), spending £41,698 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+11.60%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.10%
Asthma prevalence, PCN 3-yr % change
The asthma register records 3,276 patients (7.9% vs Ribble Valley 7.8%, ICB 7.6%, England 6.6%). Annual reviews reached 70.6% (England 65.7%) following +11.6% three-year growth (England +4.4%), though an estimated 964 patients were unreviewed. For asthma patients aged 6 to 19, second-hand smoke status recording is 71.5% (Ribble Valley 70.6%, England 78.8%). COPD prevalence is 1.9% (839 patients) with 79.5% reviewed (England 76.4%).
Cancer register and children's immunisation
The cancer register records 2,222 patients (5.1% vs Ribble Valley 5.0%, ICB 4.3%, England 3.8%). In quarterly COVER cohorts, 12-month 6-in-1 reaches 97.5% and age-5 MMR1 reaches 100.0% (England 91.0% and 91.7%). Conversely, separate 24-month cohorts fall below the 95.0% target: 6-in-1 is 88.6% (below target by 6.4 pp) and MMR1 is 87.3% (below target by 7.7 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage in NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863), trailing England (55.3%) and 22.6 pp below the 75.0% ambition. Early-stage share fell 1.2 pp since 2013, while 74.6% had a known stage (8,863 of 11,883). Reaching 75.0% requires about 2,010 extra early diagnoses annually; staging is not captured for PCNs. PCN cancer prevalence is 5.1% (England 3.8%). PCN cervical screening is 75.9% (England 66.8%), though three-year uptake fell 3.0% (England -1.0%), with Pendleside Medical Pract at 68.2%. Auditing recall systems where screening softened may support early detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, East Lancashire Hospitals NHS Trust achieved 73.2% on the 62-day standard (standard 85.0%), compared to 75.0% at Lancashire Teaching Hospitals NHS Foundation Trust, 88.9% at Airedale NHS Foundation Trust, 73.6% across the ICB and 71.2% in England. For the 28-day faster diagnosis standard (standard 75.0%), East Lancashire reached 81.5% (Lancashire Teaching 82.9%, Airedale 87.7%, ICB 78.4%, England 79.3%). Trust 6+ week diagnostic waits were 0.4% for MRI and 0.1% for CT (England 21.4% and 9.9%). Provider data reflects acute activity, not PCN performance.
| Pathways within standard (%) | East Lancashire | Lancashire | Airedale | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.50 | 82.90 | 87.71 | 78.39 | 79.32 |
| 31-day treatment (96%) | 98.11 | 89.43 | 98.20 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 73.16 | 75.04 | 88.89 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Lancashire | Lancashire | Airedale | England |
|---|---|---|---|---|
| MRI | 0.43 | 2.41 | 2.91 | 21.40 |
| CT | 0.15 | 14.97 | 0.00 | 9.92 |
| Echocardiography | 0.00 | 13.85 | 0.70 | 28.48 |
| Colonoscopy | 0.95 | 0.00 | 31.21 | 30.83 |
| Gastroscopy | 1.16 | 0.00 | 22.98 | 29.02 |
| All 15 DM01 tests | 3.25 | 26.65 | 4.33 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In June 2026 provisional community services data, adults aged 65+ accounted for 56.9% of all community contacts among Ribble Valley residents (72,000 of 126,445 contacts). This activity reflects borough residents rather than registered PCN patients, demonstrating substantial community service use among older cohorts across the area.
Practice variation and patient experience
Practice experience varies widely, spanning a 35.1 pp phone access gap across practices
QOF clinical domain achievement reached 100.0% at The Castle Medical Group, Whalley Medical Centre, and Pendleside Medical Pract, and 97.1% at Slaidburn Health Centre (England 97.1%). However, vaccination and immunisation achievement diverged by 51.6 pp, from 48.4% at Slaidburn Health Centre to 100.0% at The Castle Medical Group and Whalley Medical Centre (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Slaidburn | 106 | 0.0 | 99.3% | 72.7% | 98.8% |
| Castle Medical | 116 | 0.0 | 64.2% | 80.5% | 92.4% |
| Whalley | 120 | 0.0 | 84.9% | 86.2% | 87.6% |
| Pendleside | 135 | 0.0 | 78.5% | 75.6% | 79.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seventeen of 25 measures trail England's three-year change despite strong baseline cardiovascular control
Seventeen of 25 tracked measures trail England's three-year change. The widest relative lags are in breast screening (+3.1% vs England +8.4%), hypertension treated to target (-1.5% vs England +3.6%), and blood pressure control under age 80 (-1.0% vs England +3.2%). Mental health blood pressure checks rose +0.8 pp (England +4.4 pp). Conversely, relative strengths include asthma reviews (+11.6% vs England +4.4%), non-frail diabetes HbA1c control (+8.5% vs England +4.4%), and secondary prevention statins (+3.7% vs England +1.0%). Slower growth could reflect high baselines; clinical audit would test whether delivery has slipped.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Breast screening (53-70)
Hypertension treated to target
BP control, under 80
BP check (SMI)
Heart failure reviews
Asthma reviews
Diabetes HbA1c control
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Ribble Valley | Asset | PCN | Ribble Valley |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (499 beds) | n/a | Schools (catchment) | 38 | n/a |
| Children's centres | 2 | 3 | Places of worship | 58 | 71 |
| Libraries | 2 | 4 | Primary schools (LA maintained) | 21 | 26 |
| Primary academies | 1 | 4 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Learning disability register validation
Recorded learning disability prevalence is 0.4% (171 patients, 63.1% of the borough register), matching Ribble Valley (0.4%) and trailing the ICB (0.6%) and England (0.6%), giving a non-age-adjusted benchmark gap of +8 to +86 patients. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 2
Structured asthma review and smoke recall
Asthma reviews reached 70.6% (Ribble Valley 66.0%, ICB 65.0%, England 65.7%), leaving a scale estimate of 964 of 3,276 patients unreviewed, while 6-19 second-hand smoke recording is 71.5% (England 78.8%). For discussion, practices could add mandatory second-hand smoke prompts to asthma templates and offer after-school recall slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Cardiovascular and SMI blood pressure recall
Across 8,194 hypertension patients, target achievement is 74.9% (England 70.3%) but three-year change fell 1.5% (England +3.6%), under-80 control fell 1.0% (England +3.2%), QRISK >= 20% lipid therapy is 61.5% (England 63.6%), and SMI BP check growth (+0.8 pp) trailed England (+4.4 pp). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Inclusion health register review (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure monitoring review (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Blood pressure control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Second year immunisation recall (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Digital and phone access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 2 · Structured asthma review and smoke recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Cardiovascular and SMI blood pressure recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 · MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
